Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
基本信息
- 批准号:10478279
- 负责人:
- 金额:$ 31.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAcylationAddressAmidesAmino Acid SequenceAntibodiesAreaBindingBinding ProteinsBioinformaticsBiologicalBiologyBiomedical ResearchBrainCOVID-19 detectionCOVID-19 pandemicCatalytic AntibodiesCatalytic RNACell surfaceCellsChemicalsChemistryClinical Laboratory Information SystemsDNADNA biosynthesisDNA sequencingDataDevelopmentDiagnosticDiseaseDisease ManagementDoxorubicinEnzymesEstersEvolutionFeedbackFoundationsGPC3 geneImageIn VitroIndiaInformation SystemsKnowledgeLaboratoriesLanguageLysineMalignant neoplasm of liverMapsMeasuresMedicalMedical ResearchMedicineModificationMolecular EvolutionNational Institute of General Medical SciencesOrganic ChemistryOutcomePeptidesPerformancePharmaceutical PreparationsPhysiologicalProcessProtein EngineeringProtein Sequence AnalysisProteinsReactionReaction TimeReagentReproducibilityResearch PersonnelRestRibosomal RNARoleScienceShipsSiteSodium ChlorideSpecificitySurgeonSynthesis ChemistrySystemTechnologyTemperatureTestingThermodynamicsToxinTranslatingVisionWorkacyl groupamino groupbasebiological systemscancer cellcell killingcombinatorial chemistrydesigndrug discoverygene synthesisgenetic informationin vivoinnovationinventionmeetingsmolecular recognitionmultiplex diagnosticsnew technologynext generation sequencingprotein functionsuccesssynthetic biologytooltumorweb-based tool
项目摘要
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
Foundation for Applied Molecular Evolution
Steven Benner
ABSTRACT
Under PAR-19-253, the NIGMS seeks new technologies that create a positive feedback loop that drives
science forward by allowing new questions to be asked and new discoveries to be made, which in turn drives
the development of new technologies. The Benner group has, for 30 years, contributed to this NIGMS vision,
developing new technologies for NextGen DNA sequencing and NextGen DNA synthesis, bioinformatic and
evolutionary analyses, dynamic combinatorial chemistry for drug discovery, protein engineering, and new
platforms that make multiplexed diagnostics easy, platforms used today to manage the COVID pandemic.
Here, we offer the NIGMS another transformative tool, a platform to allow researchers to choose a
protein target and create a reagent (an AEGISZyme) that chemically transforms bound proteins. Such
reagents have been sought for 40 years with only limited success.
We will focus on one transformation: AEGISZymes that add an acyl group to an amino group on a lysine of the
bound target, where the acylation reagent is an ester. This acylation may inactivate the targeted protein, allow-
ing researchers to test hypotheses about the role of that protein in biology. It may carry a payload which, when
internalized with the target protein, carry drugs or stabilized AEGISZymes into a cell. It may fluorescently tag
the protein to help clinicians cut away fluorescing cancer cells selectively as they resect a tumor.
To achieve this transformative and innovative outcome, we will apply laboratory in vitro evolution (LIVE) to
artificially expanded genetic information systems (AEGIS). The platform will be delivered by meeting 3 Aims:
Aim 1. We will use AEGIS-LIVE to deliver AEGISZymes that acylate lysines in target proteins with pass/fail
reaction times of <10 sec-1. To test this, we will create these AEGISZymes that use a co-substrate carrying an
ester group for three targets. Rates of the selected AEGISZymes will be quantitated, specificity will be metricked
against similar targets with slightly different amino acid sequences, and modification sites will be found,
Aim 2. We will use AEGIS-LIVE to deliver AEGISZymes that acylate lysines on researcher-chosen targets with
turnover, with pass/fail turnovers of >1000 and kcat/KM of >105 M-1 sec-1. Turnover rates will be metricked
under physiological and laboratory conditions, and correlated to duplex stability from thermodynamic data.
Aim 3. We will use AEGIS-LIVE to deliver mirror AEGISZymes that are stable in biological systems, including
transport into cells. This will allow AEGISZymes to be used in biological media, to support nanotrain toxin
delivery, and to set the stage to use these molecules in vivo.
Aim 4. We will test the scope of the platform to address design parameters, such as how long random regions
should be, how good loops are as full protein surrogates, and how sequence space is searched.
Last, to lay to rest any view that AEGIS-LIVE is too "cumbersome", we will create distributable kits that allow
their recipients to make their own AEGISZymes. This is the ultimate in authentication and reproducibility.
易于使用的试剂盒,用于进化共价标记和灭活蛋白质的试剂
应用分子进化基础
史蒂文·本纳
摘要
根据PAR-19-253,NIGMS寻求新的技术,以创建一个正反馈循环,以驱动
通过允许提出新问题和发现新发现来推动科学前进,这反过来又推动
新技术的发展。30年来,本纳团队为NIGMS的愿景做出了贡献,
开发下一代DNA测序和下一代DNA合成、生物信息学和
进化分析、药物发现的动态组合化学、蛋白质工程和新技术
使多路诊断变得容易的平台,今天用于管理COVID大流行的平台。
在这里,我们为NIGMS提供了另一个变革性的工具,一个允许研究人员选择
蛋白质靶标并产生一种试剂(AEGISZyme),用于化学转化结合蛋白。是这样的
40年来,人们一直在寻找试剂,但只取得了有限的成功。
我们将专注于一种转化:AEGISZymes,它将酰基添加到赖氨酸的氨基上
结合靶,其中酰化试剂是酯。这种酰化作用可以使目标蛋白失活,从而允许-
ING研究人员测试关于该蛋白质在生物学中作用的假说。它可以携带有效载荷,当
与目标蛋白内化,携带药物或稳定的AEGISZymes进入细胞。它可以荧光标记
这种蛋白质可以帮助临床医生在切除肿瘤时有选择地切除发出荧光的癌细胞。
为了实现这一变革性和创新性的成果,我们将把实验室体外进化(LIVE)应用于
人工扩展遗传信息系统(宙斯盾)。该平台将通过满足3个目标来交付:
目标1.我们将使用Aegis-LIVE递送AEGISZymes,该AEGISZymes可以通过/失败地将目标蛋白中的赖氨酸酰化
反应时间为<;10秒-1。为了测试这一点,我们将创建这些AEGISZyme,它们使用携带有
三个目标的Ester组。选定的AEGISZyme的比率将被量化,特异性将被衡量
针对氨基酸序列略有不同的相似靶点,将找到修饰位点,
目标2.我们将使用Aegis-LIVE来交付AEGISZymes,该AEGISZymes可以将赖氨酸酰化到研究人员选择的目标上
成交量,通过/失败成交量为>;1000和kcat/km>;105M-1秒-1。流动率将被衡量
在生理和实验室条件下,并从热力学数据关联到双链稳定性。
目标3.我们将使用Aegis-LIVE交付在生物系统中稳定的镜像AEGISZyme,包括
转移到细胞内。这将允许AEGISZymes用于生物介质,以支持纳米毒素
传递,并为在体内使用这些分子奠定基础。
目标4.我们将测试平台的范围,以解决设计参数,如随机区域有多长
应该是,环作为完整的蛋白质替代品有多好,以及如何搜索序列空间。
最后,为了消除任何认为Aegis-live太“笨重”的观点,我们将创建可分发的工具包,以允许
他们的接受者制造他们自己的AEGISZymes。这是身份验证和重现性的终极要求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN A BENNER其他文献
STEVEN A BENNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN A BENNER', 18)}}的其他基金
Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
- 批准号:
10669039 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10626917 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
Basic Research for Diagnostics and Surveillance in Lower Resource Environments
低资源环境诊断和监测基础研究
- 批准号:
10468606 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins
易于使用的试剂盒可进化出共价标记和灭活蛋白质的试剂
- 批准号:
10298982 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
Equipment Supplement to 1R01GM141391-01A1 (Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins)
1R01GM141391-01A1 的设备补充(易于使用的试剂盒,用于进化共价标记和灭活蛋白质的试剂)
- 批准号:
10580301 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
PHS2019-02 Omnibus Solic of the NIH, CDC, and FDA for SBIR Apps No Clinical Trial (Parent SBIR R43/4
PHS2019-02 NIH、CDC 和 FDA 的 SBIR 应用程序综合 Solic 尚未进行临床试验(母公司 SBIR R43/4
- 批准号:
10476977 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
Reagents to Chemically Tag Specific Coronavirus Spike Proteins
化学标记特定冠状病毒刺突蛋白的试剂
- 批准号:
10259048 - 财政年份:2021
- 资助金额:
$ 31.39万 - 项目类别:
相似海外基金
Greasing endocytosis in plants - understanding the role of S-acylation in receptor kinase function and internalisation
植物中的润滑内吞作用 - 了解 S-酰化在受体激酶功能和内化中的作用
- 批准号:
BB/Y003756/1 - 财政年份:2024
- 资助金额:
$ 31.39万 - 项目类别:
Research Grant
Ghrelin de-acylation inhibitors as novel compounds for Parkinson's dementia
生长素释放肽去酰化抑制剂作为治疗帕金森痴呆症的新型化合物
- 批准号:
MR/Y503435/1 - 财政年份:2024
- 资助金额:
$ 31.39万 - 项目类别:
Research Grant
S-acylation-dependent regulation of cytokine receptor signaling and cardiac maladaptation
细胞因子受体信号传导和心脏适应不良的 S-酰化依赖性调节
- 批准号:
10561406 - 财政年份:2023
- 资助金额:
$ 31.39万 - 项目类别:
Comprehensive analysis of acidic patch binder using histone acylation catalysts
使用组蛋白酰化催化剂综合分析酸性贴片粘合剂
- 批准号:
22KJ1113 - 财政年份:2023
- 资助金额:
$ 31.39万 - 项目类别:
Grant-in-Aid for JSPS Fellows
S-Acylation of transmembrane proteins in the early secretory pathway
早期分泌途径中跨膜蛋白的 S-酰化
- 批准号:
BB/X001504/1 - 财政年份:2023
- 资助金额:
$ 31.39万 - 项目类别:
Research Grant
N-terminal acylation and sorting of Helicobacter pylori lipoproteins and their role in host response to infection
幽门螺杆菌脂蛋白的 N 末端酰化和分选及其在宿主感染反应中的作用
- 批准号:
10584620 - 财政年份:2022
- 资助金额:
$ 31.39万 - 项目类别:
The Molecular Mechanisms of Glycolytic Enzyme S-acylation in Neurons
神经元糖酵解酶S-酰化的分子机制
- 批准号:
576016-2022 - 财政年份:2022
- 资助金额:
$ 31.39万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
用于精准基因组编辑的抗 CRISPR 介导的酰化和生物可逆酯化
- 批准号:
10657417 - 财政年份:2022
- 资助金额:
$ 31.39万 - 项目类别:
High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader
YEATS2 组蛋白酰化酶抑制剂的高通量筛选
- 批准号:
10389517 - 财政年份:2022
- 资助金额:
$ 31.39万 - 项目类别:
Roles of KAT8 complexes in governing histone acylation and mouse cerebral development
KAT8复合物在控制组蛋白酰化和小鼠大脑发育中的作用
- 批准号:
RGPIN-2019-07122 - 财政年份:2022
- 资助金额:
$ 31.39万 - 项目类别:
Discovery Grants Program - Individual